Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Phase 1/2 Terminated 14 enrolled Medical College of Wisconsin

NaSingle-groupOpen-labelTreatment

Summary

This trial designed to evaluate the toxicity and efficacy of tocilizumab in the treatment of steroid refractory acute graft versus host disease (GVHD).

Timeline

Start: 2011-08-08
Primary completion: 2016-02-17
Completion: 2018-09-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	8 mg/kg	Intravenous

Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Summary

Timeline

Drugs

Indications